Hyperfine, Inc. Class A (HYPR)

Hyperfine's stock has experienced volatility and underperformed the US Medical Equipment industry and the broader US market over the past six months. In November 2025, Hyperfine reported its Q3 earnings, missing EPS and revenue expectations. In October 2025, the company raised $20.1 million through an underwritten public offering. In December 2025, Hyperfine announced FDA clearance of the first Optive AI software update and the Swoop system received regulatory approval in India. In January 2026, Hyperfine announced preliminary Q4 revenue of approximately $5.3 million, a 127% year-over-year increase, and full-year 2025 revenue of approximately $13.5 million, a 5% year-over-year increase. The company also reported a preliminary Q4 net cash burn of approximately $5.7 million and a full-year 2025 net cash burn of approximately $29.9 million.

Information explicitly detailing the demand seasonality for Hyperfine, Inc.'s specific products and services was not found. The broader portable MRI market is experiencing strong growth, driven by factors such as the adoption of decentralized healthcare, demand for imaging in remote regions, and advancements in compact magnet design, suggesting a generally increasing demand trend rather than pronounced seasonality.

Hyperfine, Inc. is a health technology company in the Medical Devices and Instruments industry, producing and commercializing MRI products. Its flagship product is the Swoop Portable MR Imaging System, the first FDA-cleared, AI-powered portable MRI for the brain. The system uses an ultra-low-field magnet and AI to produce diagnostic images at the patient's bedside. Hyperfine generates revenue through system sales and service/software subscriptions, including Optive AI™ and the Hyperfine Image Viewer. The company aims to transform patient care through accessible diagnostic imaging.

Hyperfine, Inc. serves an international market through direct sales and distributors in the United States, Canada, the United Kingdom, other European and Middle Eastern markets, Australia, New Zealand, and India. The company has received regulatory approvals, including FDA clearances in the U.S., CE Mark under the EU MDR, and UKCA certification in the United Kingdom.

Hyperfine's brand reputation has been positively impacted by several key developments and clinical milestones. The company received FDA clearance for its new next-generation Swoop system powered by Optive AI software in June 2025. In August 2025, Hyperfine achieved a clinical milestone by enrolling the 100th patient in its NEURO PMR study ahead of schedule. Hyperfine received UKCA approval for its Optive AI software in September 2025. The Swoop system received regulatory approval in India in December 2025. In January 2026, Hyperfine announced the publication of breakthrough clinical data and the enrollment of the first patient in a study to expand the intended use of the Swoop system with contrast agents. In February 2024, Hyperfine announced a collaboration with Athletic Heart to provide brain imaging screenings for current and retired professional athletes.

Hyperfine, Inc. has 54 institutional owners and shareholders holding a total of 11,286,175 shares. Major institutional owners include Vanguard Group Inc, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Fosun International Ltd, Northern Trust Corp, Alphabet Inc., VEXMX - Vanguard Extended Market Index Fund Investor Shares, Catalio Capital Management, LP, Geode Capital Management, Llc, BlackRock, Inc., and Isthmus Partners, Llc. Company insiders, including Thomas Teisseyre and Khan Siddiqui, own 26.1% of Hyperfine shares.